Literature DB >> 31896328

Misrepresenting "Usual Care" in Research: An Ethical and Scientific Error.

Ruth Macklin1, Charles Natanson2.   

Abstract

Comparative effectiveness studies, referred to here as "usual-care" trials, seek to compare current medical practices for the same medical condition. Such studies are presumed to be safe and involve only minimal risks. However, that presumption may be flawed if the trial design contains "unusual" care, resulting in potential risks to subjects and inaccurately informed consent. Three case studies described here did not rely on clinical evidence to ascertain contemporaneous practice. As a result, the investigators drew inaccurate conclusions, misinformed research participants, and subjects' safety was compromised. Before approving usual-care protocols, IRBs and scientific review committees should evaluate the quality and completeness of information documenting usual-care practices. Guidance from governmental oversight agencies regarding evidence-based documentation of current clinical practice could prevent similar occurrences in future usual-care trials. Accurate information is necessary to ensure that trials comply with government regulations that require minimizing research risks to subjects and accurate informed consent documents.

Entities:  

Keywords:  Human subjects research; IRB (Institutional Review Board); informed consent; risk/benefit analysis

Mesh:

Year:  2020        PMID: 31896328     DOI: 10.1080/15265161.2019.1687777

Source DB:  PubMed          Journal:  Am J Bioeth        ISSN: 1526-5161            Impact factor:   11.229


  2 in total

1.  Designing provider-focused implementation trials with purpose and intent: introducing the PRECIS-2-PS tool.

Authors:  Wynne E Norton; Kirsty Loudon; David A Chambers; Merrick Zwarenstein
Journal:  Implement Sci       Date:  2021-01-07       Impact factor: 7.327

2.  Protecting the mental and physical well-being of frontline health care workers during COVID-19: Study protocol of a cluster randomized controlled trial.

Authors:  Lu Dong; Lisa S Meredith; Carrie M Farmer; Sangeeta C Ahluwalia; Peggy G Chen; Kathryn Bouskill; Bing Han; Nabeel Qureshi; Sarah Dalton; Patricia Watson; Paula P Schnurr; Katherine Davis; Jonathan N Tobin; Andrea Cassells; Courtney A Gidengil
Journal:  Contemp Clin Trials       Date:  2022-04-22       Impact factor: 2.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.